Clinical trials in Amersfoort

119 clinical trials in Amersfoort, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Amersfoort at a glance

119

clinical trials

Paediatric trials0
Research sites2

Quick filters

119 trials in Amersfoort

Open in trial search

Non-small cell lung cancer stage I

Recruiting

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Small cell lung cancer

Recruiting

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Topotecan Hydrochloride
Sponsor:Zai Lab (US) LLC

Contact Research Centre

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Acute myocardial infarction

Recruiting

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Selatogrel
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study of pirtobrutinib plus epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

Study of pirtobrutinib plus epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Colorectal cancer metastatic

Recruiting

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Incyte Corp.

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Belantamab Mafodotin
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Amersfoort

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for breast cancer, prostate cancer, and leukemia. Research encompasses targeted therapies and novel drug combinations.

Breast Cancer Treatment Studies
Prostate Cancer Interventions
Hematological Malignancies

Emphasis on personalized treatment approaches and improving patient outcomes through targeted therapies.

02 Cardiovascular Studies

Research initiatives exploring cardiovascular disease management and prevention, including innovative treatments for reducing major cardiovascular events and improving patient outcomes.

Lipid Management Studies
Heart Disease Prevention
Cardiovascular Risk Reduction

Focus on developing new therapeutic approaches for cardiac conditions and preventive strategies.

03 Neurological Disorders

Clinical investigations into dementia and related conditions, studying new approaches to manage behavioral symptoms and improve patient care outcomes.

Dementia Management
Behavioral Interventions
Therapeutic Approaches

Dedicated to understanding and treating complex neurological conditions with innovative therapies.

Back to the Netherlands All countries